0.5709
price down icon2.91%   -0.0171
 
loading
Bioxcel Therapeutics Inc stock is traded at $0.5709, with a volume of 22,099. It is down -2.91% in the last 24 hours and up +3.95% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.588
Open:
$0.571
24h Volume:
22,099
Relative Volume:
0.05
Market Cap:
$23.58M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.0803
EPS:
-7.11
Net Cash Flow:
$-155.03M
1W Performance:
+9.70%
1M Performance:
+3.95%
6M Performance:
-71.60%
1Y Performance:
-85.36%
1-Day Range:
Value
$0.565
$0.5801
1-Week Range:
Value
$0.511
$0.6114
52-Week Range:
Value
$0.50
$4.17

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name
Name
Bioxcel Therapeutics Inc
Name
Phone
203-643-8060
Name
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
Employee
74
Name
Twitter
@bioxcel_tx
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BTAI 0.5709 23.58M 1.38M -179.05M -155.03M -7.11
VRTX 448.31 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.42 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.40 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.98 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.31 24.49B 3.30B -501.07M 1.03B 11.54

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-15-23 Downgrade Mizuho Buy → Neutral
Jul-17-23 Downgrade Guggenheim Buy → Neutral
Mar-10-23 Downgrade Jefferies Buy → Hold
Dec-01-22 Upgrade Goldman Sell → Neutral
Jul-07-22 Initiated Mizuho Buy
Apr-06-22 Reiterated BofA Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-09-21 Initiated Berenberg Buy
Feb-01-21 Initiated UBS Buy
Oct-30-20 Initiated Goldman Buy
Sep-02-20 Initiated Jefferies Buy
Aug-17-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Reiterated H.C. Wainwright Buy
Jun-04-20 Initiated Guggenheim Buy
Apr-01-20 Initiated BofA/Merrill Buy
Feb-26-20 Reiterated H.C. Wainwright Buy
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-12-19 Initiated SunTrust Buy
View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

pulisher
Nov 18, 2024

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 18, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

BioXcel advances trials for acute agitation treatments - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 08, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire

Nov 08, 2024
pulisher
Nov 05, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN

Nov 05, 2024
pulisher
Oct 30, 2024

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com

Oct 30, 2024
pulisher
Oct 29, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 23, 2024

BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World

Oct 23, 2024
pulisher
Oct 19, 2024

BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN

Oct 19, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan

Oct 15, 2024
pulisher
Oct 10, 2024

BioXcel Therapeutics reports executive transition - Investing.com India

Oct 10, 2024
pulisher
Oct 09, 2024

BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily

Oct 09, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia

Oct 04, 2024
pulisher
Oct 04, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada

Oct 03, 2024
pulisher
Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com

Oct 03, 2024

Bioxcel Therapeutics Inc Stock (BTAI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):